Neurolutions
Neurolutions is a medical device company that developed IpsiHand, the first FDA-cleared non-invasive Brain-Computer Interface for at-home upper extremity rehabilitation in chronic stroke survivors. Now operating under Kandu, Inc. following a March 2025 merger, it sells the DME-classified system through Medicare, VA, and private reimbursement channels.
- Company typePrivate
- Founded2007
- HeadquartersVan Nuys, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Neurolutions does
Neurolutions is a medical device company founded in 2007 as a spinout from Dr. Eric Leuthardt's lab at Washington University in St. Louis. Following a March 2025 merger with Kandu Health, the company operates under the Kandu, Inc. parent while maintaining the Neurolutions brand and the IpsiHand product identity. Its core offering is IpsiHand, the first FDA-cleared (De Novo, 2021) non-invasive Brain-Computer Interface system for at-home upper extremity rehabilitation in chronic stroke survivors (≥6 months post-stroke, age 18+). The system comprises three components: a wireless handpiece worn on the affected hand, a non-invasive EEG headset that captures 'intention to move' signals from the uninjured brain hemisphere, and a tablet that guides daily treatment and tracks progress. The therapy is grounded in Hebbian Theory and motor priming, with theta-gamma phase-amplitude coupling validated as a cortical biomarker of recovery. CMS classifies IpsiHand as Durable Medical Equipment under HCPCS code E0738, and the system is covered on a case-by-case basis by Medicare, the VA, and many private health plans.
Neurolutions generates revenue primarily through hardware sales of the IpsiHand system as a DME product, bundled with ongoing clinical support services including monthly OT-facilitated community meetings, in-person screening events, and a dedicated insurance navigation team. The go-to-market model is hybrid: enterprise field sales targeting clinicians and clinical sites for in-services and prescription generation, paired with direct-to-consumer channels where patients self-refer via the company website, screening events, and dedicated support. The primary end customer is the chronic stroke survivor; the secondary customer is the prescribing clinician. Headcount is 11–50 employees, with the leadership team combining neuroscience and medical device commercialization expertise (CEO Leo Petrossian; CSO Dr. Eric Leuthardt; CFO Nabeel Ahmed; CMO Dr. Tudor Jovin; CCO Andy Schultz; CBO Calvin Portley; CIO Seth Wilk; COO Javad Seyedzadeh; CMO/GM Kirsten Carroll).
The company is in early commercial scaling. IpsiHand completed limited launch in 2023, full market launch in 2024, and received a dedicated CMS reimbursement code plus DME classification in 2025. Capital structure includes a $26.55M round (March 2025), an undisclosed round from Amed Ventures (2018), a $1.15M round led by Ascension Ventures, BioGenerator, and Prolog Ventures (2015), a $100K seed from St. Louis Arch Angels (2012), a $2M NIH SBIR grant (2020), and a January 2026 strategic growth investment from K2 HealthVentures and Piper Sandler Merchant Bank. Clinical evidence includes randomized controlled trials published in Brain Communications and Brain-Computer Interfaces journals, with 100% of subjects demonstrating improvement on primary outcome measures and 66.7% exceeding MCID across all studies.
Neurolutions firmographics
Firmographics- Name
- Neurolutions
- Legal name
- Neurolutions, Inc.
- Website
- https://neurolutions.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neurolutions is a medical device company that developed IpsiHand, the first FDA-cleared non-invasive Brain-Computer Interface for at-home upper extremity rehabilitation in chronic stroke survivors. Now operating under Kandu, Inc. following a March 2025 merger, it sells the DME-classified system through Medicare, VA, and private reimbursement channels.
- Ownership category
- akta.pro rank
Neurolutions industry classification
Industry- Product category
- Neurorehabilitation Medical Devices
- NAICS
- Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134), Home Health Care Services (62161)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industries
- Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s) (HLADAJAH), Neurorehabilitation Centers (HLAFAFAH)
Keywords
Where Neurolutions is headquartered
LocationHeadquarters
- HQ city
- Van Nuys
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Neurolutions business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- IpsiHand Hardware System Sales (DME): Neurolutions sells the IpsiHand Upper Extremity Rehabilitation System as a durable medical equipment (DME) product. CMS classified IpsiHand as DME, enabling Medicare coverage under HCPCS code E0738. The system is covered on a case-by-case basis by many health plans including Medicare and the VA. Revenue is generated from the sale of the hardware system (handpiece, headset, tablet), with the company's support team handling insurance navigation.
- Clinical and Support Services: Neurolutions provides ongoing clinical support including monthly community support meetings facilitated by an occupational therapist, real-time technical and clinical support, in-person screening events, and patient enrollment support. These services are bundled with the device sale to ensure proper use and positive outcomes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | IpsiHand Upper Extremity Rehabilitation System (hardware + support) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Neurolutions product offering
Product offeringCore offering
Neurolutions develops and sells the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared (De Novo) non-invasive brain-computer interface (BCI) designed for at-home rehabilitation of arm and hand motor function in chronic stroke survivors (adults at least 6 months post-stroke). The system comprises a wireless handpiece, a non-invasive EEG headset, and a tablet that together enable thought-activated therapy by translating the user's 'intention to move' signals from the uninjured brain hemisphere into mechanical hand movement, facilitating neuroplasticity and motor recovery.
Product overview
Neurolutions offers a single core product—the IpsiHand Upper Extremity Rehabilitation System—which is an FDA-cleared brain-computer interface (BCI) designed for at-home rehabilitation of upper extremity motor function in chronic stroke survivors. The system comprises three integrated components: the IpsiHand Headset (non-invasive EEG device capturing brain signals), the IpsiHand Handpiece (wireless mechanical hand assist device), and the IpsiHand Tablet (user interface and progress tracking). The company was formed from a merger of Neurolutions and Kandu Health in March 2025, operating under Kandu Inc.
Differentiator
Problem solved
Functional benefit
Brands
- IpsiHand: The IpsiHand Upper Extremity Rehabilitation System is an FDA-cleared, non-invasive brain-computer interface device for rehabilitation of upper extremity motor function in chronic stroke survivors. It comprises a handpiece, headset, and tablet components that enable thought-activated therapy at home.
Products and services
- IpsiHand Upper Extremity Rehabilitation System An FDA-cleared, non-invasive brain-computer interface (BCI) system for at-home rehabilitation of arm and hand motor function in chronic stroke survivors. The system detects the user's intention to move via EEG signals from the uninjured brain hemisphere and mechanically assists hand movement via a wireless handpiece, facilitating neuroplasticity and motor recovery. It is classified by CMS as Durable Medical Equipment under HCPCS code E0738 and is covered by Medicare, VA, and many private health plans on a case-by-case basis.
Quantifiable outcome
- Approximately 70% of clinical trial participants improved arm and hand movement
- +5 more outcomes
Companies that use Neurolutions
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Neurolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Neurolutions partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Kandu HealthcoreNeurolutions merged with Kandu Health to form Kandu, Inc., a healthcare technology company focused on stroke rehabilitation. The merger combined Neurolutions' IpsiHand BCI technology with Kandu Health's stroke care platform and clinical services. Kirsten Carroll, founder and CEO of Kandu Health, became CMO and General Manager of Clinical Services at the combined entity. The merged company is headquartered in Van Nuys, CA.
- Washington University in St. LouiscoreNeurolutions was established out of Dr. Eric Leuthardt's lab at Washington University in St. Louis. The company was built on WashU discoveries, with initial funding support from Ascension Health Ventures. WashU startups including Neurolutions attracted record $1.7 billion in private-sector investment over the past year.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Neurolutions competitors and assessment
Company assessmentDirect peers
- MindMaze: MindMaze develops digital neurotherapeutics and neurorehabilitation platforms for stroke and brain injury recovery. Directly comparable to Neurolutions as a neuro-rehab technology company targeting post-stroke upper extremity and cognitive recovery with software- and hardware-enabled therapy.
- Hocoma (DIH): Hocoma (now part of DIH) is a leading neurorehabilitation device maker (Lokomat, Armeo). Directly comparable as a global provider of clinical upper-extremity and gait neurorehab equipment sold to hospitals and rehab centers.
- Ekso Bionics: Ekso Bionics develops wearable exoskeletons and robotic rehabilitation devices for stroke and spinal cord injury. Directly comparable as a publicly listed neurorehabilitation robotics company targeting upper and lower extremity motor recovery.
- Bionik Laboratories: Bionik Laboratories makes robotic rehabilitation devices (InMotion ARM) for upper extremity stroke recovery. Directly comparable as a neurorehab robotics company focused on post-stroke arm/hand motor retraining in clinical settings.
- BrainCo: BrainCo develops non-invasive EEG-based BCI products for rehabilitation, education, and prosthetics. Directly comparable as a non-invasive BCI peer using EEG to drive rehabilitation outcomes.
- Nexstim: Nexstim provides navigated transcranial magnetic stimulation (nTMS) systems used in stroke rehabilitation and neurosurgery planning. Directly comparable as a non-invasive brain stimulation company in the neurorehab space targeting chronic stroke motor recovery.
- Saebo: Saebo manufactures upper extremity orthoses and rehab devices (SaeboGlove, SaeboStretch) for stroke survivors. Directly comparable as a company selling at-home upper-limb stroke rehabilitation devices through clinicians and direct-to-patient channels.
- Tyromotion: Tyromotion produces robotic and sensor-based upper-extremity rehabilitation devices (e.g., Armeo Power) used in clinical neurorehab. Directly comparable as a neurorehab device vendor focused on upper-limb motor recovery for stroke patients.
Emerging players
- Synchron: Synchron is a BCI company developing a minimally invasive endovascular neural interface, primarily targeting paralysis. Comparable as a leading BCI peer aiming for FDA clearance in motor-restoration applications, though its delivery model (implanted stent) differs from IpsiHand's non-invasive EEG approach.
- Blackrock Neurotech: Blackrock Neurotech builds high-channel invasive BCI systems for research and clinical applications including motor restoration. Comparable as a BCI category peer focused on motor rehabilitation, though it currently serves research channels rather than at-home chronic stroke patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurolutions social profiles
Digital presenceNeurolutions compliance and trust
Trust signalCompliance7 records
Neurolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurolutions leadership team
Management profileNumber of profiles
Profiles19 records
Neurolutions funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurolutions
What does Neurolutions do?
Neurolutions develops and sells the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared (De Novo) non-invasive brain-computer interface (BCI) designed for at-home rehabilitation of arm and hand motor function in chronic stroke survivors (adults at least 6 months post-stroke). The system comprises a wireless handpiece, a non-invasive EEG headset, and a tablet that together enable thought-activated therapy by translating the user's 'intention to move' signals from the uninjured brain hemisphere into mechanical hand movement, facilitating neuroplasticity and motor recovery.
Is Neurolutions a public or private company?
Neurolutions is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurolutions founded?
Neurolutions was founded in 2007. It employs 11 to 50 people.
Where is Neurolutions based?
Neurolutions is headquartered in Van Nuys, United States, in the North America region.
How does Neurolutions make money?
Two revenue lines are on record. IpsiHand Hardware System Sales (DME) is the primary driver. The others are clinical and Support Services.
Who are Neurolutions's main competitors?
Direct peers on record are MindMaze, Hocoma (DIH), Ekso Bionics, Bionik Laboratories, BrainCo, Nexstim, Saebo and Tyromotion. Emerging players are Synchron and Blackrock Neurotech.
Does Neurolutions have an API?
No public API is recorded for Neurolutions.
What industry is Neurolutions in?
Neurolutions's product category is Neurorehabilitation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLACANAJ, Digital Rehabilitation & Physical Therapy Therapeutics. Its NAICS code is 62134 and its SIC code is 3845.